Overview

Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.

Phase:

PHASE2

Details

Lead Sponsor:

Anhui Provincial Hospital

Treatments:

Basiliximab